- Supported exchanges /
- F /
- 7SS.F
Brii Biosciences Limited (7SS F) stock market data APIs
Brii Biosciences Limited engages in the research and development of therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, BRII-835, and BRII-877, which are in Phase 2 the development of a functional cure for HBV for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 2; and BRII-732 that is in Phase 1 clinical trial and BRII-753, which is in preclinical stage for the treatment of HIV. It develops BRII-296 for the treatment of PPD/MDD, anxiety, and other depressive disorders; BRII-297 for treatment of various depressive disorders; BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for oral treatment for patients with chronic NTM lung disease. Brii Biosciences Limited was incorporated in 2017 and is headquartered in Beijing, China.
Brii Biosciences Limited Financial Data Overview
| 0.116 | |
| 0.116 | |
| - | |
| 0.116 | |
| 0.116 | |
| 0.102-0.358 | |
| 92 250 K | |
| 731 M | |
| 38 380 K | |
| 1.452 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Brii Biosciences Limited Fundamental Data is available in our Financial Data APIs
- Net Revenue 38 380 K
- EBITDA -488 484 000
- Earnings Per Share -0.05
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Brii Biosciences Limited Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get Brii Biosciences Limited End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
